Pharmaceuticals

Alzheimer’s Drugs Market Overview 2026–2030 With Insights On Industry Developments

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Alzheimer’s Drugs Market During 2026–2030?

The alzheimer’s drugs market size has demonstrated robust expansion recently. Projections indicate it will grow from $10.09 billion in 2025 to $10.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. This historical growth can be attributed to an expanding elderly population, the rising prevalence of Alzheimer’s disease, increasing awareness of dementia care, the limited treatment options available in earlier periods, and continuous advances in neuroscience research.

The alzheimer’s drugs market size is predicted to undergo significant expansion over the next few years. It is projected to increase to $15.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This anticipated growth within the forecast period is attributable to advancements in precision medicine, the integration of AI in drug development, the expansion of healthcare infrastructure, robust government support and funding for dementia research, and the rising adoption of digital health monitoring solutions. Dominant trends during this period are expected to include the development of personalized alzheimer’s therapies, innovations in neuroprotective drugs, improved early diagnosis and screening solutions, the introduction of combination and multi-target drugs, and enhanced patient adherence and monitoring solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Key Factors Are Shaping The Alzheimer’s Drugs Market Landscape?

The growing occurrence of Alzheimer’s disease is anticipated to boost the expansion of the Alzheimer’s drugs market moving ahead. This neurological condition, Alzheimer’s disease, progressively deteriorates, leading to both brain atrophy and cellular demise. Medications specifically for Alzheimer’s disease address issues such as memory impairment, challenges with cognitive processes like thinking and reasoning, and hindrances in daily activities. These Alzheimer’s medications have the potential to improve an individual’s quality of life and support their autonomy. For example, in May 2024, a report from the Alzheimer’s Association, a US-based nonprofit organization focused on Alzheimer’s care, support, and research, indicated that the count of Americans aged 65 and older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the escalating occurrence of Alzheimer’s disease is fueling the expansion of the Alzheimer’s drugs market.

What Are The Key Segment Divisions In The Alzheimer’s Drugs Market Segment Structure?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Which Trends Are Impacting The Progress Of The Alzheimer’s Drugs Market?

Leading companies in the Alzheimer’s drugs market are introducing innovative products, such as amyloid plaque-targeting therapy, to enhance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy is a therapeutic strategy for Alzheimer’s disease focused on reducing or preventing the accumulation of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, secured approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency tasked with protecting public health. Kisunla (donanemab-azbt) represents the first and only amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. It functions by helping the body remove excess amyloid plaques from the brain, which are associated with cognitive decline in Alzheimer’s patients. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.

Which Organizations Are Engaged In The Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.

Get The Full Alzheimer’s Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Which Region Leads The Alzheimer’s Drugs Market In Overall Market Size?

North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Drugs Market 2026, By The Business Research Company

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795